Bleomycin SulfateThird Party Manufacturing in India

Bleomycin Sulfate is a glycopeptide antibiotic that works by causing oxidative damage to DNA, leading to strand breakage and cancer cell death. Unlike most anticancer drugs, bleomycin chelates metal ions, particularly iron, to form an activated complex that binds to DNA. In the presence of oxygen, this bleomycin-iron complex generates reactive species that abstract a hydrogen atom from the deoxyribose sugar of DNA, triggering a cascade of chemical reactions that ultimately break the DNA strand. Bleomycin produces both single-strand and double-strand breaks in DNA, with the double-strand breaks being particularly lethal to cancer cells. The drug is cell cycle phase-specific, primarily killing cells in the G2 and M phases of the cell cycle. A distinctive feature of bleomycin is that it is inactivated by an enzyme called bleomycin hydrolase, which is abundant in most normal tissues but present at low levels in the lungs and skin. This differential distribution explains why bleomycin causes characteristic toxicity in these organs while sparing many others. The drug is most effective against squamous cell carcinomas, lymphomas, and testicular tumors.

Therapeutic Uses

Bleomycin Sulfate is prescribed for the treatment of:

• Hodgkin's Lymphoma: A key component of the ABVD chemotherapy regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), which is the standard first-line treatment for Hodgkin's lymphoma.
• Testicular Carcinoma: Effective against testicular germ cell tumors including embryonal cell carcinoma, choriocarcinoma, and teratocarcinoma, as part of the BEP regimen (Bleomycin, Etoposide, Cisplatin).
• Non-Hodgkin's Lymphoma: Used in the treatment of intermediate and high-grade non-Hodgkin's lymphoma, particularly in combination with other chemotherapeutic agents.
• Squamous Cell Carcinoma: Used for squamous cell cancers of the head and neck, cervix, and skin, administered intravenously, intramuscularly, or subcutaneously.

Why Manufacturers Choose Bleomycin Sulfate

Bleomycin Sulfate is an established oncology drug listed on the WHO Essential Medicines List, ensuring sustained global demand. It is a critical component of curative chemotherapy regimens for Hodgkin's lymphoma and testicular cancer. For Indian manufacturers with cytotoxic injectable production capabilities and lyophilization facilities, bleomycin sulfate represents an important addition to an oncology injectable portfolio. The standard 15 IU vial formulation is in consistent demand from hospital oncology departments and cancer care centers across India and export markets.

This makes Bleomycin Sulfate one of the most important oncology injectables for third party manufacturing in India, with consistent demand from cancer hospitals, PCD franchise operators, and international tender business.